Ectica Technologies welcomes you to the Proventa International Oncology R&D Strategy Meeting &more
Updated: Jan 26
PROVENTA INTERNATIONAL ONCOLOGY R&D STRATEGY MEETING
Ectica Technologies is excited to sponsor the 5th Annual Oncology Strategy Meeting organized by Proventa International taking place on May 17th 2022 at the Le Meridien Cambridge (Massachusetts USA). Proventa’s R&D Strategy Meetings provide you with the right environment to make important connections with executives and senior managers through interactive roundtable discussions, exclusive networking and keynote panel debates. The goal of the Oncology R&D Strategy meetings is to explore promising areas in oncology research to expand our knowledge base, address unmet medical needs and improve overall clinical success. The thematic focus will be on precision medicine, biomarker discovery and companion diagnostics.
Contact us or visit our conference page to receive a free-pass to access this great event and take the opportunity to to discuss with us partnerships to address tumor-stroma interaction in drug discovery and research .
PREDiCT 7th Annual 3D TISSUE MODELS SUMMIT
Ectica Technologies and SCREEN Holdings are jointly exhibiting at the PREDiCT 7th Annual 3D TISSUE MODELS SUMMIT taking place from May 10th to 12th 2022 at the Hilton Boston Back Bay (Massachusetts USA).
The conference attracts world experts looking at integrating advanced 3D models with scalability and predictability. Key aspects discussed during the meeting include iPSC 3D cell culture models, drug screening technologies and maximization of clinical translatability.
Please visit the contact page to schedule a meeting with us!
Tomographic imaging of organotypic cultures developed in the 3DProSeed hydrogel plate
Ectica Technologies and SCREEN will present their joint work related to label-free 3D tomographic imaging of organotypic cultures developed in the 3DProSeed hydrogel plate. The use of advanced ex vivo human organotypic cultures is rapidly growing in the field of oncology research and diagnostics, with a focus on patient-derived organoids and tumor tissue specimens cultured in artificial systems capable of replicating tumor development mechanisms. These mechanisms include metastasis, angiogenesis and formation of dysplasia. Our objective is to enhance the label-free imaging and analytical capabilities of these complex tissue samples to enable screening and diagnostics applications.
About SCREEN Holdings Co. Ltd technology
SCREEN Holdings Co Ltd has developed a unique infrared laser-based optical coherence tomography (technology equipped with an 890 nm center wavelength) light from a super luminescent diode and an objective (NA=0.3 high magnification lens), thereby, enabling non invasive, label-free, three dimensional 3D) imaging of tumoroids, epithelial cystic organoids, sprouting endothelial neo vasculature and metastatic single cells. We present culture and imaging protocols with the resulting 3D tomographic reconstructions of endothelial sprouting vessels, cystic epithelial organoids of the colon and 3D invasion assays of highly metastatic glioma cells.
About Ectica Technologies and 3DProSeed hydrogel plate
The 3DProSeed hydrogel plate developed by Ectica Technologies offers the highest workflow integration in screening processes. No hydrogel assembly step is necessary: the hydrogels are pre-casted in the plate and delivered hydrated and ready for cell seeding. Thanks to the patented hydrogel surface, no cell encapsulation procedures are required. Additionally, the hydrogels, made of poly(ethylene glycol)-based bioconjugates, are fully synthetic and animal free and offer the highest control over the culture conditions, as well as the possibility to upgrade to GMP for cell therapy applications. Finally, various cell populations can be sequentially seeded at different time points to generate complex co-cultures. In this way, stromal environments can be created under controlled conditions, to which cancer cells can be subsequently added.